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AtherosclerosisAbstract Objectives: The aim of this study is assessment of plasma apelin levels in patients with
coronary artery disease (CAD) before and after percutaneous coronary intervention (PCI).
Methods: The present study is conducted on 40 patients who underwent PCI, beside 20 healthy
subjects with no risk factors or any evidence of CAD. After history taking each subject in the study
underwent an electrocardiography, echocardiography for calculation of the left ventricular ejection
fraction (LVEF). 22 patients underwent PCI with drug eluting stent (DES), while 18 patients under-
went PCI with bare metal stents. Plasma apelin level was estimated for the control group, before,
and 24 h after PCI in the patient’s group.
Results: Baseline plasma apelin level was higher in the control group versus the PCI group
(385.4 ± 94.86 vs. 286.8 ± 52.93 ng/ml, p< 0.0001).There was signiﬁcant rise in plasma apelin lev-
els post PCI (428.4 ± 153.21 vs. 286.8 ± 52.93 ng/ml, p< 0.0001). There was no signiﬁcant differ-
ence in plasma apelin levels pre and post PCI in patients undergoing PCI with DES versus those
with bare metal stents. There were no signiﬁcant correlations between plasma apelin levels pre
PCI with age, gender, hypertension (HTN), diabetes mellitus, smoking, BMI, plasma cholesterol,
creatinine, blood sugar level, and LVEF.
Conclusion: Apelin level increased after PCI in CAD patients, which could be an adaptive reaction
for the endothelium recovery.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Cardiology.1. Introduction
Percutaneous coronary intervention (PCI) has become the pre-
dominant procedure for coronary revascularization in patients
with both stable and unstable coronary artery disease (CAD).
Despite immediate relief of the vessel obstruction by PCI, the
disrupted endothelium and the mechanical tension of the
media/adventitia result in adverse clinical outcomes due to ves-
64 A.A. Abdelaziz et al.sel thrombosis, remodeling, and the development of neointimal
hyperplasia.1,2
Apelin is a recently discovered peptide, identiﬁed as an
endogenous ligand of receptor APJ. Apelin and receptor APJ
are expressed in a wide variety of tissues including the heart,
brain, kidneys and lungs.3,4 In the cardiovascular system, ape-
lin and APJ receptors occur in vascular smooth muscle, endo-
thelial cells, and cardiomyocytes.5 Apelin has three major
actions in the human cardiovascular system: endothelium-
dependent vasodilatation; direct vasoconstriction by interact-
ing with smooth muscle APJ receptor and increased cardiac
contractility by action on cardiac myocytes.6
Apelin causes peripheral vasodilatation by an endothelial
nitric oxide (NO)-dependent pathway.7,8 The wide distribution
of apelin and APJ throughout the body and its predominant
localization in vascular endothelium mirror the distribution
of angiotensin II receptor type 1 (AT1).9 The physiological
effects of apelin are opposite to the actions of angiotensin-II.
Therefore apelin acting through the APJ receptor may modu-
late the detrimental effects of the AT1 activation and help to
prevent progressive left ventricular systolic dysfunction and
the onset of heart failure. It has been hypothesized that apelin
secretion slows down the process of adverse left ventricular
remodeling by maintaining cardiac output and reducing
afterload.10
Pitkin et al. have shown an increase in apelin expression in
atherosclerotic coronary artery, with the additional peptide
localizing to the atherosclerotic plaque. Apelin receptor was
also found to be present within the atherosclerotic plaque
and to have a similar distribution to its ligand.11 Increased
content of apelin and its receptor might be an indicator of
increased anti-inﬂammatory activation of macrophages
thereby limiting plaque instability. Due to lack of data and
contradictory ﬁndings, the exact role of apelin on atherosclero-
sis plaque remains inconclusive.11
The possible involvement of apelin in the pathogenesis of
high prevalence conditions and comorbidities such as hyper-
tension, heart failure, and Diabetes Mellitus Type 2 rank it
as a likely therapeutic target to be investigated in the
future.12–14
The aim of our study is to evaluate plasma apelin levels in
patients with CAD before and after percutaneous coronary
intervention.
2. Patients and methods
2.1. Study population
A prospective, controlled study was conducted on 40 patients,
who underwent percutaneous coronary intervention in our
catheterization laboratory, Mansoura Medical Specialized
hospital, Mansoura University, Egypt between January 2013
and August 2013. The protocol was approved by our ethics
committee, and a written consent was taken from the study
subjects.
Entry criteria included patients with chronic stable angina
and stenosis of more than 70% in at least one major epicardial
coronary artery with symptoms consistent with myocardial
ischemia (chest pain, dyspnea) in spite of medical therapy.
We further enrolled 20 healthy subjects, who had no risk fac-
tors such as hypertension, DM, and dyslipidemia, with no evi-dence of CAD, and they were treated with no medications as
the control group.
2.2. Exclusion criteria
- Left ventricular ejection fraction less than 40%.
- Patients with left main CAD.
- Acute myocardial infarction and primary PCI.
- Patients with an acute coronary syndrome 614 days.
- Cardiogenic shock.
- Valvular heart disease.
- Conduction disturbance.
- Liver and renal impairment.
- Autoimmune and neoplastic diseases.
The studied patients were subjected to history taking espe-
cially for the characteristics of chest pain and risk factors for
CAD including diabetes mellitus, hypertension, smoking, and
family history of CAD and drug history including aspirin,
clopidogrel, statins, ACEI, diuretics, and beta blockers. All
patients received clopidogrel and aspirin before the procedure.
2.3. Electrocardiography
Standard 12-lead ECG was analyzed for site and extent of
ischemia and old myocardial infarction.
2.4. Echocardiography
Patients and controls were examined at rest in supine left lat-
eral decubitus positions using GE (vivid 3 pro) Norway using
2.5 MHZ phased array transducer following the recommenda-
tion of the American society of echocardiography for the pres-
ence of wall motion abnormality and calculation of LV
ejection fraction using the biplane method according to the
modiﬁed Simpsons rule.15
2.5. Coronary angiography
Coronary angiography and PCI were performed via the femo-
ral approach using a standard Judkins technique for all studied
patients. Obstructive CAD was deﬁned as the stenosis of epi-
cardial coronary artery P70% by coronary angiography.
PCI was performed in the standard fashion. 22 patients under-
went PCI with drug eluting stent (DES), zotarolimus-eluting
stent, while 18 patients underwent PCI with bare metal stents.
All patients included in the study had undergone successful
procedures, deﬁned as a percentage diameter of residual steno-
sis of <20% in two orthogonal views.16
2.6. SYNTAX score calculation
Based on the baseline diagnostic angiogram, each coronary
lesion producing P50% diameter stenosis in vessels
P1.5 mm was scored separately, and these scores were added
together to provide the overall SYNTAX score, which was cal-
culated using the SYNTAX score algorithm.17 This algorithm
is available on the SYNTAX website. All diagnostic angio-
grams were scored by two experienced cardiologists who were
Table 1 Baseline characteristics of patients with CAD.
CAD group (n= 40)
Age (years), mean ± SD 56.05 ± 7.04
Gender (male) 30 (75%)
Hypertension n (%) 24 (60%)
Diabetes mellitus n (%) 16 (40%)
Smoking n (%) 22 (55%)
BMI (kg/m2) 25.3 ± 9.45
SBP (mmHg) 145 ± 12.6
DBP (mmHg) 80 ± 11.3
Old anterior MI
Old inferior MI
Unstable angina
18 (45%)
14 (35%)
8 (20%)
LV EF (%) 54.25 ± 8.20
Cholesterol (mg/dl) 223.2 ± 74.1
Creatinine (mg/dl) 0.91 ± 0.15
Fasting blood sugar (mg/dl) 104.65 ± 25.38
Drugs
Beta blockers
ACEI
Statins
Diuretics
32 (80%)
30 (75%)
26 (65%)
12 (30%)
BMI = body mass index, SBP = systolic blood pressure, DBP
diastolic blood pressure, LVEF= left ventricular ejection fraction.
Table 2 Coronary angiographic and lesion characteristics.
PCI group (n= 40)
Number of vessels undergoing PCI
LAD
LCX
RCA
LAD and LCX
LAD and RCA
18 (45%)
6 (15%)
10 (25%)
4 (10%)
2 (5%)
Mean percent diameter stenosis 79.75 ± 8.54
Number of stents (mean) 1.37 ± 0.58
Stent length (mm) 22.85 ± 6.9
Stent diameter (mm) 3.07 ± 0.26
Syntax score 16.25 ± 3.5
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agreement, the opinion of the third observer was obtained and
the ﬁnal decision was made by consensus.
2.7. Laboratory data
After taking a medical consent, 10 ml venous blood samples
were collected in ethylenediamine-tetra-acetic acid (EDTA)
tubes prior to PCI for measurement of plasma apelin, creati-
nine, cholesterol and fasting glucose. And another sample
was taken 24 h after PCI for measurement of plasma apelin
levels. After separation of samples in a cooling centrifuge
and spun at 3000 rpm for 10 min at 2–8 C plasma was
extracted and frozen in aliquots at 80 C until analysis.
Apelin assay was performed using the Apelin-12 microplate
ELISA assay kit (Glory Science co., Del Rio, TX 78840, USA)
according to manufacturer’s instructions. In order to measure
the concentration of AP12 in the sample, this AP12 ELISA Kit
includes a set of calibration standards. The calibration stan-
dards are assayed at the same time as the samples and allow
the operator to produce a standard curve of Optical Density
versus AP12 concentration. The concentration of AP12 in
the samples is then determined by comparing the optical den-
sity of the samples to the standard curve. The antibody used in
this apelin assay cross-reacts 100% with Apelin-12, 13 and
36.The assay therefore includes all of the above peptides if
present in the plasma. The sensitivity of the assay was
0.1 ng/ml.
2.8. Statistical analysis
All data were analyzed using a SPSS software package (version
17.0, SPSS Inc. Chicago, IL, USA). Continuous variables were
expressed as mean ± SD, and categorical variables were
expressed as percentage. Comparisons of apelin level pre and
post PCI were performed using the paired t-test. Pearson corre-
lation coefﬁcients were used to explore relationships between the
apelin level and different clinical and angiographic data. P value
of <0.05 was considered statistically signiﬁcant. Receiver oper-
ating characteristic (ROC) curve was used to detect the cut-off
value plasma apelin that predict patients with CAD.
3. Results
3.1. Study population
We included 40 CAD patients who underwent PCI, their mean
age was 56.05 ± 7.04 years, 75% were males, 60% had hyper-
tension, 40% had diabetes mellitus, 55% were smokers, BMI
was 25.3 ± 9.45, 45% had old anterior wall myocardial infarc-
tion (MI), 35% had old inferior wall MI, 20% had past history
of unstable angina. Their mean LVEF was 54.25 ± 8.20. The
mean plasma creatinine was 0.91 mg/dl, fasting blood sugar
was 104 mg/dl, and total serum cholesterol was 223 mg/dl.
80% were on beta-blocker, 75% received ACEI, 65% received
statins, and 30% were receiving diuretics (Table 1).
3.2. PCI procedure
The coronary angiography and PCI data are summarized in
Table 2. 22 patients underwent PCI with DES, while 18patients underwent PCI with bare metal stents. Percutaneous
coronary interventions were performed in left anterior
descending artery (LAD) 45%, left circumﬂex artery (LCX)
15%, right coronary artery (RCA) 25%, both LAD
and LCX 10%, and in both LAD and RCA 5%. The mean
percent diameter of stenosis was 79.75 ± 8.54, stent length
was 22.85 ± 6.9 mm, the mean stent diameter was 3.07 ±
0.26 mm, and the syntax score was 16.25 ± 3.5.
3.3. Plasma apelin
Baseline plasma apelin level was higher in the control group
compared to the CAD group before PCI (385.4 ± 94.86 ng/
ml vs. 286.8 ± 52.93 ng/ml, p< 0.0001, Table 3, Fig. 1).
There was a signiﬁcant rise in plasma apelin levels post PCI
(428.4 ± 153.21 ng/ml vs. 286.8 ± 52.93 ng/ml, p< 0.0001).
There were no signiﬁcant differences in plasma apelin levels
pre and post PCI in patients undergoing PCI with DES versus
those with bare metal stents (Table 3).
Table 3 Plasma apelin levels in patients and the control
group.
Apelin (ng/ml) t P
CAD group (n= 40)
Control group (n= 20)
286.8 ± 52.93
385.4 ± 94.86
4.32 0.0001
Before PCI (n = 40)
After PCI (n= 40)
286.8 ± 52.93
428.4 ± 153.21
6.82 0.0001
Apelin before PCI
DES (n= 22)
Bare metal stent (n= 18)
291.1 ± 61.34
281.4 ± 41.52
0.574 0.569
Apelin after PCI
DES (n= 22)
Bare metal stent (n= 18)
443.9 ± 197.03
409.5 ± 72.17
0.701 0.488
Table 4 Correlation of plasma apelin level before PCI with
different clinical data.
r P
Age (years) 0.088 NS
Gender (male) 0.307 NS
Hypertension n (%) 0.261 NS
Diabetes mellitus n (%) 0.303 NS
Smoking n (%) 0.297 NS
BMI (kg/m2) 0.312 NS
LV EF 0.180 NS
Cholesterol (mg/dl) 0.024 NS
Creatinine (mg/dl) 0.211 NS
Fasting blood sugar (mg/dl) 0.103 NS
Table 5 Correlation of plasma apelin levels post PCI with
angiographic and lesion characteristics data.
r P
Stent type 0.113 NS
Number of vessels undergoing PCI 0.199 NS
Mean percent diameter stenosis 0.084 NS
Number of stents (mean) 0.323 0.042
Stent length (mm) 0.116 NS
Stent diameter (mm) 0.037 NS
Syntax score 0.292 NS
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There were no signiﬁcant correlations between plasma apelin
levels pre PCI with age, gender, hypertension, diabetes melli-
tus, smoking, BMI, plasma cholesterol, creatinine, blood sugar
level, and LVEF (Table 4). There was signiﬁcant positive cor-
relation between plasma apelin levels post PCI and number of
stents used (p< 0.042, Table 5), while there was no signiﬁcant
correlation between plasma apelin levels post PCI and the stent
type, number of vessels undergoing PCI, mean percent diame-
ter stenosis, stent length, and syntax score.
The Receiver-operating characteristic curve (ROC) for
basal plasma apelin level as a predictor of CAD showed that
plasma apelin with a cutoff point of 285 ng/ml yielded an area
under the curve (AUC) of 0.810, p< 0.0001, with a sensitivity
of 90% and speciﬁcity of 55% (Fig. 2).
4. Discussion
In our study plasma apelin levels were signiﬁcantly decreased
in CAD patients compared to controls. This indicates downFigure 1 Baseline plasma apelin inregulation of apelin and APJ expression in patients with
CAD which may have pathophysiologic implications in
CAD patients. Similar results were observed by Li et al. who
showed that the plasma apelin levels in patients with stable
angina pectoris were lower than the control.18 Tycinase et al.
noticed the trend to decrease the values of apelin within the
ﬁrst 5-day interval of AMI after 1ry PCI, regardless to left ven-
tricular dysfunction.19 Kadoglou et al. revealed that apelin
concentrations were lower in CAD patients as compared topatients and the control group.
Figure 2 Receiver operating characteristic curve (ROC) for the ability of basal plasma apelin to predict CAD.
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niﬁcantly lower levels of apelin compared to the patients with
asymptomatic coronary artery disease. Moreover, apelin con-
centrations were inversely associated with the severity and
the acute phase of CAD, which suggests its involvement in
the progression and destabilization of coronary atherosclerotic
plaques.20
We found an increase in plasma apelin levels post PCI. Sim-
ilar results were observed by Du et al. who revealed signiﬁcant
increase in hs-CRP and apelin post PCI with sirolimus eluting
stent but they include patients with LVEF less than 40% in
their study. They also showed that LVEF was the only variable
that independently related to the degree of post procedure ape-
lin elevation.21
The up regulation of apelin post PCI might have cardio
protective properties. As the importance of apelin in modulat-
ing normal and pathologic angiogenesis is being revealed, ape-
lin up-regulation after angioplasty suggests that it may play a
protective pathophysiologic role after endothelium injury.
Apelin and vascular endothelial growth factor are associated
with mobilization of endothelial progenitor cells (EPCs) after
PCI in response to endothelial perturbation, and inﬂammatory
response. Early EPCs possess the capacity to home to sites of
vascular injury, to produce neoangiogenesis in vivo and to
maintain the homeostasis of vascular endothelium.22 The
angiogenic activity of apelin may result from the combination
of the molecule to APJ, playing a role in the proliferation,
migration, and tube formation of endothelial cells.23 In addi-
tion, apelin activates cell transduction cascades such as ser-
ine/threonine kinase (Akt) and extracellular signal-regulated
kinases (ERKs),24,25 which lead to the proliferation of endo-
thelial cells and the formation of new blood vessels.26
In our study the lack of difference in apelin levels pre and
post PCI with DES in comparison to bare metal stents raisesthe possibility of similar inﬂammatory response during the acute
phase post PCI with either DES or bare metal stent. PCI induces
a systemic inﬂammatory response caused by injury to the arterial
wall. Apelin exerts acute anti-inﬂammatory effects on the vascu-
lar system; and suppresses the production of proinﬂammatory
cytokines.27 Delayed endothelialization after DES implantation
resulted in persistent endothelial dysfunction, and increased
vasoconstrictive response early post-DES implantation, together
with profound impairment of the endothelium dependent vaso-
dilation and decrease in endothelium independent vasodila-
tion.28,29 The rise in apelin concentrations post PCI may also
indicate similar abnormal endothelial-dependent vasoreactivity
to both DES and bare metal stents. Further studies are needed
to elaborate if the increase in apelin levels was transient during
the acute phase post PCI or persist.
In our study there was no correlation between apelin level
and LVEF. This ﬁnding could be attributed to our small sam-
ple size, also we exclude patients with LVEF < 40%. The
positive correlation between plasma apelin and number of
stents used mainly attributed to the degree of inﬂammatory
response early post PCI.
5. Conclusion
Apelin level increased after PCI in CAD patients, which could
be an adaptive reaction for the endothelium recovery. The
pathophysiological effects of apelin post PCI, and the possible
therapeutic applications such as the use of agonists to promote
therapeutic angiogenesis need further study.
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